The global legal cannabis industry is no longer an emerging market, but a maturing one with established regulatory frameworks, institutional capital, and a growing ecosystem of professional services.
Europe’s medical cannabis market alone is projected to reach €2.28 billion by 2029, up from €1.09 billion in 2025, according to Prohibition Partners research. For entrepreneurs and investors looking to enter the sector, the opportunity is real, but so is the complexity.
This guide covers the key steps involved in starting a cannabis business, from choosing your market and structure to navigating regulation, technology, and funding.
Cannabis businesses operate across several distinct verticals. These range from cultivation to processing and manufacturing, retail (dispensaries), distribution, testing, and ancillary services like technology, consulting, and finance. Each carries different capital requirements, regulatory obligations, and margin profiles.
Your first decision is geography. Regulatory environments vary dramatically by country and, in federal systems, by state or region.
In the United States, cannabis remains federally controlled under Schedule I of the Controlled Substances Act, meaning operators must navigate a patchwork of state licensing regimes.
Throughout the majority of countries in Europe, medical cannabis is legal and growing fast. Germany is now the continent’s largest medical cannabis market, valued at an estimated €222 million in 2025, and is in the early stages of adult-use reform, with cannabis social clubs now permitted under the 2024 Cannabis Act.
The UK, the next fastest growing market in the region, similarly operates a prescription-only medical model through private clinics, but with an entirely separate regulatory framework.
Switzerland, Malta, and the Netherlands are progressing adult-use frameworks, with varying levels of opportunity for businesses.
Understanding which licence you need before you do anything else will determine your path. Cultivation, processing, retail, and research licences each involve different regulatory bodies, timeframes, and fees.
Unlike most industries, cannabis businesses must design compliance into the business model from day one, not retrofit it later. This means engaging with regulators early, mapping the full licence application process, and building timelines that account for regulatory delays.
As a key example, in the UK, every single import shipment requires its own separate application and approval, creating an ongoing compliance cost that constrains supply and keeps prices elevated.
For those considering cultivation, meeting EU pharmaceutical-grade (GMP) microbial standards is demanding enough that even well-capitalised growers may need to irradiate product to qualify, a process that adds cost and complexity before a single unit reaches a patient.
In Germany, the shift from pharmacy-only dispensing to broader access models is still evolving and will shape retail strategies significantly.
A robust business plan should include a full compliance roadmap, legal counsel familiar with cannabis regulation, and contingencies for regulatory change.
Cannabis businesses face unique funding constraints that differ from almost every other sector. In the United States, the absence of federal legalisation means most traditional banks refuse to work with plant-touching cannabis companies. More than 80% of US dispensaries remain cash-dependent as a result, creating high operational and security costs.
Operators have adapted by working with specialist cannabis-friendly credit unions and payment processors, but this landscape remains fragmented.
In Europe, the situation is somewhat better for medical cannabis companies, particularly those structured around pharmaceutical-grade products, as these may access conventional financial services. Investors considering the sector should model banking costs carefully and build in contingency for evolving payment infrastructure.
Technology is not optional in regulated cannabis markets, it is a compliance requirement. US operators alone must navigate more than 12 distinct technology categories, including point-of-sale (POS), enterprise resource planning (ERP), track-and-trace, payments, customer relationship management (CRM), seed-to-sale software, HR and payroll, marketing, e-commerce, analytics, and more.
Track-and-trace systems are mandated in all US states with adult-use or medical programmes. The two dominant platforms, Metrc and BioTrack, together cover most of the market. Metrc charges approximately $0.45 per tag; BioTrack charges $0.10. These are recurring operational costs that must be factored into unit economics.
The European cannabis tech landscape is less mature but growing. Companies such as Cannavigia, a Swiss platform that describes itself as a ‘digital twin’ of cannabis operations, covering compliance, documentation and quality control, are targeting producers and operators in pharmaceutical-grade regulated markets.
Where the US tech ecosystem evolved around dispensary retail, European equivalents are being built around GMP documentation and supply chain traceability, reflecting the medical-only regulatory environment most European operators work within.
When building your tech stack, consider the Build/Buy/Integrate framework. Most operators should buy off-the-shelf software for standard functions (POS, payroll) and integrate via APIs where possible. Building proprietary systems only makes sense at scale for genuinely differentiated capabilities.
Between 2020 and 2024, there were 35 mergers and acquisitions in the US digital cannabis sector, reflecting rapid consolidation in the tech layer. Choosing platforms with strong integration ecosystems reduces the risk of being stranded on discontinued software.
Many early cannabis businesses underestimate operational complexity. Regulated markets require meticulous record-keeping, strict inventory management, staff training and background checks, security infrastructure, and real-time reporting to regulators. These are not back-office tasks, they are core operations.
Building for scale means designing systems that can grow with your license footprint. If you plan to open multiple dispensary locations, your POS and inventory systems must support multi-site management from the outset. If you plan to cultivate and retail, your seed-to-sale platform must cover the full supply chain.
Starting a cannabis business is a serious commercial undertaking that rewards preparation. The markets are growing, Europe’s medical sector is on course to more than double in four years, but they are also tightening regulatory standards and consolidating rapidly.
Operators who enter with a clear market focus, a compliance-first mindset, a realistic funding plan, and the right technology infrastructure will be best positioned to compete.
The window for early-mover advantage is narrowing. But for well-prepared businesses, significant opportunity remains.
The post How to Start a Cannabis Business: A Complete Guide appeared first on Business of Cannabis.
Continue reading...
Europe’s medical cannabis market alone is projected to reach €2.28 billion by 2029, up from €1.09 billion in 2025, according to Prohibition Partners research. For entrepreneurs and investors looking to enter the sector, the opportunity is real, but so is the complexity.
This guide covers the key steps involved in starting a cannabis business, from choosing your market and structure to navigating regulation, technology, and funding.
1. Choose your market and licence type
Cannabis businesses operate across several distinct verticals. These range from cultivation to processing and manufacturing, retail (dispensaries), distribution, testing, and ancillary services like technology, consulting, and finance. Each carries different capital requirements, regulatory obligations, and margin profiles.
Your first decision is geography. Regulatory environments vary dramatically by country and, in federal systems, by state or region.
In the United States, cannabis remains federally controlled under Schedule I of the Controlled Substances Act, meaning operators must navigate a patchwork of state licensing regimes.
Throughout the majority of countries in Europe, medical cannabis is legal and growing fast. Germany is now the continent’s largest medical cannabis market, valued at an estimated €222 million in 2025, and is in the early stages of adult-use reform, with cannabis social clubs now permitted under the 2024 Cannabis Act.
The UK, the next fastest growing market in the region, similarly operates a prescription-only medical model through private clinics, but with an entirely separate regulatory framework.
Switzerland, Malta, and the Netherlands are progressing adult-use frameworks, with varying levels of opportunity for businesses.
Understanding which licence you need before you do anything else will determine your path. Cultivation, processing, retail, and research licences each involve different regulatory bodies, timeframes, and fees.
2. Build a regulation-first business plan
Unlike most industries, cannabis businesses must design compliance into the business model from day one, not retrofit it later. This means engaging with regulators early, mapping the full licence application process, and building timelines that account for regulatory delays.
As a key example, in the UK, every single import shipment requires its own separate application and approval, creating an ongoing compliance cost that constrains supply and keeps prices elevated.
For those considering cultivation, meeting EU pharmaceutical-grade (GMP) microbial standards is demanding enough that even well-capitalised growers may need to irradiate product to qualify, a process that adds cost and complexity before a single unit reaches a patient.
In Germany, the shift from pharmacy-only dispensing to broader access models is still evolving and will shape retail strategies significantly.
A robust business plan should include a full compliance roadmap, legal counsel familiar with cannabis regulation, and contingencies for regulatory change.
3. Secure funding and understand the banking challenges
Cannabis businesses face unique funding constraints that differ from almost every other sector. In the United States, the absence of federal legalisation means most traditional banks refuse to work with plant-touching cannabis companies. More than 80% of US dispensaries remain cash-dependent as a result, creating high operational and security costs.
Operators have adapted by working with specialist cannabis-friendly credit unions and payment processors, but this landscape remains fragmented.
In Europe, the situation is somewhat better for medical cannabis companies, particularly those structured around pharmaceutical-grade products, as these may access conventional financial services. Investors considering the sector should model banking costs carefully and build in contingency for evolving payment infrastructure.
4. Invest in the right technology stack
Technology is not optional in regulated cannabis markets, it is a compliance requirement. US operators alone must navigate more than 12 distinct technology categories, including point-of-sale (POS), enterprise resource planning (ERP), track-and-trace, payments, customer relationship management (CRM), seed-to-sale software, HR and payroll, marketing, e-commerce, analytics, and more.
Track-and-trace systems are mandated in all US states with adult-use or medical programmes. The two dominant platforms, Metrc and BioTrack, together cover most of the market. Metrc charges approximately $0.45 per tag; BioTrack charges $0.10. These are recurring operational costs that must be factored into unit economics.
The European cannabis tech landscape is less mature but growing. Companies such as Cannavigia, a Swiss platform that describes itself as a ‘digital twin’ of cannabis operations, covering compliance, documentation and quality control, are targeting producers and operators in pharmaceutical-grade regulated markets.
Where the US tech ecosystem evolved around dispensary retail, European equivalents are being built around GMP documentation and supply chain traceability, reflecting the medical-only regulatory environment most European operators work within.
When building your tech stack, consider the Build/Buy/Integrate framework. Most operators should buy off-the-shelf software for standard functions (POS, payroll) and integrate via APIs where possible. Building proprietary systems only makes sense at scale for genuinely differentiated capabilities.
Between 2020 and 2024, there were 35 mergers and acquisitions in the US digital cannabis sector, reflecting rapid consolidation in the tech layer. Choosing platforms with strong integration ecosystems reduces the risk of being stranded on discontinued software.
5. Plan for operational scale from the start
Many early cannabis businesses underestimate operational complexity. Regulated markets require meticulous record-keeping, strict inventory management, staff training and background checks, security infrastructure, and real-time reporting to regulators. These are not back-office tasks, they are core operations.
Building for scale means designing systems that can grow with your license footprint. If you plan to open multiple dispensary locations, your POS and inventory systems must support multi-site management from the outset. If you plan to cultivate and retail, your seed-to-sale platform must cover the full supply chain.
The bottom line
Starting a cannabis business is a serious commercial undertaking that rewards preparation. The markets are growing, Europe’s medical sector is on course to more than double in four years, but they are also tightening regulatory standards and consolidating rapidly.
Operators who enter with a clear market focus, a compliance-first mindset, a realistic funding plan, and the right technology infrastructure will be best positioned to compete.
The window for early-mover advantage is narrowing. But for well-prepared businesses, significant opportunity remains.
The post How to Start a Cannabis Business: A Complete Guide appeared first on Business of Cannabis.
Continue reading...
